Email LinkedIn Twitter

Pharmaceutical Industry Report Sheds Light on Gray Areas of Scientific Publications Process

CHAPEL HILL, N.C., Nov. 9, 2018 /PRNewswire/ -- Medical publications are an important and credible means of communicating relevant scientific information about a pharmaceutical company's existing and pipeline products to healthcare professionals.

However, pharma and biotechnology companies encounter potential gray areas when it comes to authorship selection for articles and handling author transitions to another company or institution.

To provide current insights around these time-consuming and important issues, Best Practices, LLC undertook benchmarking research to examine the industry's current approach to authorship selection. This new research study reviews the standards, processes and rationale of critical authorship selection and retention decisions. Publications leaders can use this research to shape their publication policies to avoid uncertainties and delays.

Specifically, this study provides insights on guidance on the removal of an author from the publication, when an author is leaving for a competitor/non-competitor, circumstances under which former employee is allowed to remain lead author, and specification of authorship rights in employment contract.

In the study, a majority of companies said they don't balance the ratio of internal to external authors since ICMJE criteria don't differentiate between them. The study also found that there is no agreement on who is the best arbiter for determining who will be invited to be an author, although some type of group (publication team or trial-steering committee) is used by 48%.

"
Authorship Selection for Medical Publications at Pharmaceutical and Biotech Companies" will serve as a reference for medical publication leaders to shape their authorship transition guidelines.

Key topics in the 48-page study include:
  • Criteria and Process for Different Types of Publications
  • Defining, Tracking, and Recording Author Contributions
  • Process for Internal vs. External Authors
  • Guidance for Transitioning Authors
  • Joining a Competitor vs Non-competitor
  • Guidance for Transitioning KOLs

For this study, Best Practices, LLC engaged 23 leaders from biopharmaceutical companies and a publication services consultancy in this benchmarking research. The study has two data segments: Large Companies and Small to Medium Companies.

To access the full report or to download a complimentary summary containing insights found in this report, click on the following link:
https://www.best-in-class.com/rr1519.htm.

For related research, visit the Best Practices, LLC Web site at
https://www.best-in-class.com/.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.

 
ACCESS AND INTELLIGENCE FOR ACHIEVING WORLD-CLASS EXCELLENCE
Quick Links  Product RSS Feed
Payment gateway
Secured by PayPal

Follow Us: 

linkedin twitter slideshare youtube google + pinterest

All contents copyright 1998-2020 Best Practices, LLC (919) 403-0251
Read our Terms and Conditions of Use, Privacy Policy and Copyright Information